These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14600527)

  • 1. Polylactic acid implants. A new smile for lipoatrophic faces?
    Boix V
    AIDS; 2003 Nov; 17(17):2533-5. PubMed ID: 14600527
    [No Abstract]   [Full Text] [Related]  

  • 2. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly-L-lactic acid.
    Perry CM
    Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical Pearl: The use of a laboratory vortex for poly-L-lactic acid injection.
    Leonard AL; Hanke CW
    J Am Acad Dermatol; 2006 Sep; 55(3):511-2. PubMed ID: 16908361
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients.
    Lafaurie M; Dolivo M; Porcher R; Rudant J; Madelaine I; Molina JM
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):393-8. PubMed ID: 15764955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of facial lipatrophy].
    Hilton S
    MMW Fortschr Med; 2009 Apr; 151(18):40-2, 44. PubMed ID: 19769074
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-l-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman.
    Burgess CM
    Dermatol Surg; 2009 May; 35(5):881-4. PubMed ID: 19389088
    [No Abstract]   [Full Text] [Related]  

  • 12. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly-L-lactic acid: a perspective from my practice.
    Sadick NS
    J Cosmet Dermatol; 2008 Mar; 7(1):55-60. PubMed ID: 18254813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 39-year-old man with HIV-associated lipodystrophy.
    Fuller J
    JAMA; 2008 Sep; 300(9):1056-66. PubMed ID: 18677013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soft tissue augmentation using sculptra.
    Humble G; Mest D
    Facial Plast Surg; 2004 May; 20(2):157-63. PubMed ID: 15643584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy.
    Wildemore JK; Jones DH
    Dermatol Surg; 2006 Nov; 32(11):1407-9; discussion 1409. PubMed ID: 17083596
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
    Guaraldi G; Orlando G; De Fazio D; De Lorenzi I; Rottino A; De Santis G; Pedone A; Spaggiari A; Baccarani A; Borghi V; Esposito R
    Antivir Ther; 2005; 10(6):753-9. PubMed ID: 16218175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.